Actively Recruiting
Evaluating the Safety and Effectiveness of TP-06 Ophthalmic Solution Compared to Placebo in Adults With Persistent Corneal Epithelial Defects
Led by Tarsus Pharmaceuticals, Inc. · Updated on 2026-10-21
32
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 2 trial to compare TP-06 2.0% ophthalmic solution with a placebo vehicle in adults who have persistent corneal epithelial defects PCED that have not healed after at least 10 days of standard treatment. This trial aims to evaluate the safety and effectiveness of TP-06 in promoting corneal healing, improving visual acuity, and assessing changes in corneal thickness. Participants will be randomly assigned to receive either TP-06 2.0% or the vehicle four times daily for 8 weeks, alongside required background therapy. After the treatment phase, there will be a 2-week follow-up period to monitor healing and safety. The study is double-masked and involves multiple centers. During the study, participants will undergo assessments including evaluation of corneal healing through fluorescein staining, measurement of lesion size with imaging, and tests of visual acuity. Researchers will monitor the timing and extent of corneal healing and any safety concerns. The total participation time includes 8 weeks of treatment plus 2 weeks of follow-up.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Research Team
S
Study Director
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here